- Home
- EXG vs RYTM Comparison
EXG vs RYTM Comparison
Compare EXG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXG
- RYTM
- Stock Information
- Founded
- EXG 2007
- RYTM 2008
- Country
- EXG United States
- RYTM United States
- Employees
- EXG N/A
- RYTM N/A
- Industry
- EXG Finance Companies
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- EXG Finance
- RYTM Health Care
- Exchange
- EXG Nasdaq
- RYTM Nasdaq
- Market Cap
- EXG 2.6B
- RYTM 4.3B
- IPO Year
- EXG N/A
- RYTM 2017
- Fundamental
- Price
- EXG $8.75
- RYTM $63.62
- Analyst Decision
- EXG
- RYTM Strong Buy
- Analyst Count
- EXG 0
- RYTM 12
- Target Price
- EXG N/A
- RYTM $77.50
- AVG Volume (30 Days)
- EXG 533.2K
- RYTM 560.2K
- Earning Date
- EXG 01-01-0001
- RYTM 08-05-2025
- Dividend Yield
- EXG 8.27%
- RYTM N/A
- EPS Growth
- EXG N/A
- RYTM N/A
- EPS
- EXG N/A
- RYTM N/A
- Revenue
- EXG N/A
- RYTM $136,863,000.00
- Revenue This Year
- EXG N/A
- RYTM $37.56
- Revenue Next Year
- EXG N/A
- RYTM $74.99
- P/E Ratio
- EXG N/A
- RYTM N/A
- Revenue Growth
- EXG N/A
- RYTM 48.88
- 52 Week Low
- EXG $6.78
- RYTM $40.46
- 52 Week High
- EXG $8.15
- RYTM $69.89
- Technical
- Relative Strength Index (RSI)
- EXG 64.12
- RYTM 46.09
- Support Level
- EXG $8.40
- RYTM $60.70
- Resistance Level
- EXG $8.77
- RYTM $64.00
- Average True Range (ATR)
- EXG 0.07
- RYTM 2.22
- MACD
- EXG -0.00
- RYTM -0.39
- Stochastic Oscillator
- EXG 94.59
- RYTM 8.11
About EXG Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.